- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03622827
Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer (ChESS)
Postoperative Concurrent Chemoradiotherapy Combined With Recombinant Human Endostatin for High-risk Early Stage Cervical Cancer: A Phase II Pilot Study (ChESS).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a pilot phase 2, single arm study to assess the efficacy and safety of concurrent chemoradiotherapy combined with recombinant human endostatin (Endostar) in early stage cervical cancer patients with high risk factor(s).
Postoperative pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total prescription dose of 45-50Gy to PTV region. The external beam radiotherapy should be completed within 6 weeks. Concurrent chemotherapy consists of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks. Recombinant human endostatin (Endostar,15mg/m2/d, civ, d1-7) is applied 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.
Aimed to recruit total of 120 cases in this single arm study. The primary endpoint is 3-year disease-free survival and acute toxicity. Secondary endpoints include time to distant metastasis survival, local-regional recurrence free survival, 3 and 5-year overall survival, and safety and tolerability. Quality of life will be evaluated with EORTC-Q30.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ke Gu, M.D., Ph.D
- Número de teléfono: 86-13405070898
- Correo electrónico: dr.guke@hotmail.com
Copia de seguridad de contactos de estudio
- Nombre: Zhiliang Ding, M.D.
- Número de teléfono: 86-18913535515
Ubicaciones de estudio
-
-
Jiangsu
-
Suzhou, Jiangsu, Porcelana, 215001
- Reclutamiento
- The Affiliated Suzhou Hospital of Nanjing Medical University
-
Contacto:
- Ke Gu, M.D., Ph.D
- Número de teléfono: 86-13405070898
- Correo electrónico: dr.guke@hotmail.com
-
Contacto:
- Zhiliang Ding, M.D.
- Número de teléfono: 86-18913535515
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Aged between 18 and 70 years.
- Histologically confirmed adenocarcinoma or squamous cervical carcinomas.
- Chest CT scan and ultrasound must be done prior to surgery as to rule out distant metastasis.
- Operable patients with clinical diagnosis of FIGO stage IB-IIA cervical cancer.
- Complete radical hysterectomy of cervical cancer is mandatory. All gross diseases must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Para-aortic lymph node sampling is performed according to gynaecologist decision.
- Patients with one of these risk factors:positive pelvic nodes, parametrial invasion, positive surgical margin.OR patients with at least two of following risk factors: tumor size≥4cm,lymphovascular space invasion,stromal invasion≥1/2.
- Performance status 0-2 (ECOG, Eastern Cooperative Oncology Group).
- Adequate organ function is needed, including cardio-respiratory, hepato-renal and hematological reserves: Absolute neutrophil count (ANC)≥1.5×109/L;Platelet count≥100×109/L; ASAT&ALST<1.5 times upper limit of normal (ULN) (With hepatic metastases, ASAT&ALST<5.0 times upper limit of normal);Bilirubin <1.5 times ULN;Creatinine≤1.25×ULN or Creatinine clearance≥50 mL/min.
- Signed written informed consent prior to study entry.
Exclusion Criteria:
- Previous radiation or chemotherapy treatment or major pelvic surgery.
- Patients with distant metastasis confirmed by imaging or pathology.
- Other uncured malignant tumors in the past five years, except the cured skin basal cell carcinoma and breast carcinoma in situ.
- Any prior anticancer therapy.
- Unable to tolerate postoperative concurrent chemoradiotherapy.
- Patients with evidence of being allergic to fluorouracil, cisplatin or Endostar.
- Patients with serious comorbidity that might potentially influence the practice of protocol, including severe infection, myocardial infarction, severe arrhythmia, severe cerebrovascular disease, severe mental disorder, etc.
- Patients with Heart related adverse events or thrombotic events in the past 6 months.
- Patients with hepatitis B, hepatitis C and human immunodeficiency virus (HIV) or any other active viral infections.
- Participate in other clinical researchers.
- The estimated survival<3 months;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Chemoradiotherapy + Endostar
Chemoradiotherapy with Endostar:
|
Chemoradiotherapy with Endostar:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
3-year Disease-free survival
Periodo de tiempo: 3 years
|
From date of surgery until the date of first documented local-regional progression or distant metastasis (determined by CT or MRI scan and/or biopsy) or death (from any cause) assessed up to three years.
|
3 years
|
Acute toxicity
Periodo de tiempo: 3 months
|
Evaluate the treatment induced toxicity according to CTCAE 4.0 during the time of chemoradiotherapy and Endostar which starts from the first day of Endostar and lasts three months.
|
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to distant metastasis survival
Periodo de tiempo: 3 years
|
Determine the non-distant metastasis survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first distant metastasis event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
Local-regional recurrence free survival
Periodo de tiempo: 3 years
|
Determine the local-regional recurrence free survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first local-regional recurrence event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
3-year overall survival rate
Periodo de tiempo: 3 years
|
Determine the 3-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 3 years after operation.
|
3 years
|
5-year overall survival rate
Periodo de tiempo: 5 years
|
Determine the 5-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 5 years after operation.
|
5 years
|
Quality of Life (QoL)
Periodo de tiempo: 3 years
|
Collect QoL data on early-stage cervical cancer patients with high risk factors.
The data is measured by EORTC QLQ-C30 (Version 3.0) according to investigator collection at the starting and ending time of the adjuvant treatment.
EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
The core and disease-specific for cervix modules are selected to estimate treatment related influence on patients' life.
The final score of the questionnaire is collected and analyzed according to detailed scoring procedures from manuals.
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ke Gu, M.D., Ph.D, The Affiliated Suzhou Hospital of Nanjing Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias Uterinas
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Enfermedades uterinas
- Neoplasias del cuello uterino
- Efectos fisiológicos de las drogas
- Agentes antineoplásicos
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Proteína endoestrella
Otros números de identificación del estudio
- K2018009
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Neoplasias del cuello uterino
-
Stanford UniversityTerminadoCirugía Cervical Posterior | Fusión cervical posterior | Laminectomía cervical posterior | Laminoplastia Cervical PosteriorEstados Unidos
-
Gazi UniversityReclutamientoRadiculopatía cervical | Dolor radicular cervical | Radiculitis cervical | Síndrome de la raíz cervicalPavo
-
Valérie SchuermansReclutamientoEnfermedad del disco cervical | Fusión cervical | Fusión de columna | Espondilosis cervical | Hernia de disco cervical | Mielopatía cervical | Degeneración del disco cervical | Radiculopatía Cervical | Mielopatía Compresiva | Radiculopatía, Región Cervical | Radiculopatía; en espondilosis | Radiculopatía; en... y otras condicionesPaíses Bajos
-
Blaz BarunReclutamientoLesión por latigazo cervical de la columna cervicalCroacia
-
University of IcelandLandspitali University Hospital; Reykjavik University; Empowered HealthActivo, no reclutandoLesión por latigazo cervical de la columna cervicalIslandia
-
NuVasiveInscripción por invitaciónRadiculopatía cervical | Enfermedad del disco cervical | Enfermedad de la columna cervical | Mielopatía cervical | Espondilosis cervical | Hernia de disco cervical | Estenosis cervicalEstados Unidos
-
Istanbul Medipol University HospitalTerminadoDolor | Radiculopatía cervical | Enfermedad del disco cervical | Hernia de disco cervical | Dolor radicular cervical | Cervical; HerniaPavo
-
University of MichiganWashington University School of Medicine; LFR InternationalTerminadoLesión de la vértebra cervical | Fractura de vértebra cervicalEstados Unidos
-
Western Galilee Hospital-NahariyaReclutamiento
-
Imperial College Healthcare NHS TrustImperial College London; The Wellington Hospital, LondonTerminado
Ensayos clínicos sobre Chemoradiotherapy+ Endostar
-
Eastern Hepatobiliary Surgery HospitalTerminadoCarcinoma hepatocelular | Trombo tumoral de la vena portaPorcelana
-
Affiliated Hospital of North Sichuan Medical CollegeJiangsu Simcere Pharmaceutical Co., Ltd.Desconocido
-
Simcere Pharmaceutical Co., LtdThe Affiliated Changzhou Tumor Hospital of Suzhou UniversityDesconocidoNeoplasias colorrectalesPorcelana
-
Tianjin Medical University Cancer Institute and...TerminadoSarcoma de tejido blando, adulto, estadio IIBPorcelana
-
Shanghai Jiao Tong University School of MedicineDesconocidoCáncer colorrectal avanzadoPorcelana
-
Rennes University HospitalReclutamientoEnsayo clínico | Hogares de ancianos | ComidaFrancia
-
Yuhong LiTerminadoCarcinoma de células escamosas de esófagoPorcelana
-
Yun-fei XiaDesconocidoEl carcinoma nasofaríngeoPorcelana
-
Simcere Pharmaceutical Co., LtdDesconocidoMelanomas avanzados | Pacientes no tratadosPorcelana
-
Hunan Province Tumor HospitalDesconocidoCáncer de pulmón de células no pequeñasPorcelana